P95 held its annual retreat in Mallorca

At the beginning of October, we held our Annual Retreat in beautiful Mallorca. Around 100 employees were present! This was a great opportunity to network, meet our colleagues, discuss past, present and future of P95, acknowledge our diversity, and party together. What a wonderful couple of days!

 


A tour of our new P95 Latina office

We're excited to share a quick tour of our new P95 Latina office in Bogotá, Colombia, which opened in August 2022. The office provides a tailored space for our local team to meet, work together, or share a coffee. This is a new step toward strengthening our Latina branch office, a little over a year after its creation, and we hope our colleagues will make the most of it.

 


P95 presents 5 posters at the International Conference on Lyme Borreliosis 2022

The P95 Lyme Team (Leah Burn, MPHJehidys Montiel RamosAura Victoria Gutiérrez RabáThao Mai Phuong Tran) presented 5 posters at the International Conference on Lyme Borreliosis (ICLB 2022) in Amsterdam, the Netherlands from Sept. 4th to 7th.

The posters were:

[P027] Incidence of Lyme Borreliosis in Europe from National Public Health Surveillance Systems (2005-2020)

[P028] Worldwide epidemiology of Lyme of disease outside the regions of North America, Europe, and China: A systematic review (2005-2020)

[P029] Incidence of Lyme Borreliosis in Europe, a systematic literature review (2005-2020)

[P030] Seroprevalence of Lyme Borreliosis in Europe: results from a systematic review (2005-2020)

[P047] Incidence of Lyme Disease in Asia from National Public Health Surveillance Systems (2011—2020)

P95 authors are on 6 total poster presentations at ICLB2022

 


P95 featured in the GIZ’s 2021 Integrated Company Report

The Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH's 2021 Integrated Company Report highlights the international training program to enhance vaccine pharmacovigilance capacity in low and middle-income countries developed last year as a joint effort between P95 and GIZ. Through this initiative, our company contributed its knowledge and expertise on pharmacovigilance and vaccine safety and effectiveness studies, while GIZ provided support to roll out of the training through an international network, which included health agencies and experts from Ecuador, Ghana and Morocco.
You can find more on this initiative, featuring our team lead Zuleika Aponte (she/her/ella/elle), here: https://reporting.giz.de/2021/our-work-around-the-world/global-health/greater-vaccination-safety


DRIVE project comes to an end

After five years, the Development of Robust and Innovative Effectiveness (DRIVE) project has come to an end. Set up in July 2017, DRIVE’s main goal was to establish a sufficiently sized network for robust, high-quality, brand-specific IVE estimates for all vaccines used in the EU in each season. After the project's end, all the partners involved expect its legacy to continue through the development of a vaccine monitoring framework in the EU.

P95 was an active consortium partner in DRIVE, leading the work on the annual influenza vaccine effectiveness studies, performing the statistical analysis of the data and authoring the annual reports. In addition, the P95 IT-team developed a GDPR-compliant secure environment for repository of the sites' datasets and for data analysis. P95’s participation was led by Anke Stuurman.

DRIVE formed the basis for COVIDRIVE, a brand-specific COVID-19 vaccine effectiveness platform, co-founded and co-coordinated by P95.


P95 celebrates its 11th birthday

On June 16h, 2022, P95 turned 11 years old! To everyone who has allowed our company to achieve this milestone, thank you! We are so excited to celebrate one more year doing what believe in: finding, analysing and reporting epidemiological data to help health agencies, research organisations and pharma companies in their quest to improve people’s access to safe and effective vaccines. We are proud of the achievements that the past 11 years have brought and look forward to the future. Here’s to many more years working together, new wonderful projects and contributions to public health.


P95 Latina team meets in Bogota

On the week of  May 16th to May 20th, some of the Epidemiology and Medical Writing team leads met the P95 Latina team in Bogota for a productive work week, which also included presentations from each team member sharing their experiences in different P95 projects and, of course, some quality in-person time together. The team also took this opportunity to celebrate the first P95 Latina anniversary, and we hope this was the first of many more celebrations of our company's growth in other parts of the world.

 


“We saw in Latin America a hub of talented professionals in epidemiology and research”

In this new interview, Adriana Bastidas, Regional Medical Director, and Blanca Escobar, Regional Head of Operations, talk about the creation of P95 Latina, the first branch office of P95 in Latin America, the interests that led them to Colombia, and the process of creating an office on the other side of the Atlantic.

Expanding to a different region is the dream of any growing company. For P95, the opportunity arose last year, when Adriana Bastidas, Regional Scientific Director and Blanca Escobar, Regional Study Operations lead, took on the challenge of creating P95 Latina, the first branch office of P95 outside Europe. Based in Colombia, where an important hub for clinical research and epidemiology in the region was identified, P95 Latina started operations in April 2021 and now counts with nine epidemiologists and one medical editor. In this interview, Adriana and Blanca explain the process of creating P95 Latina, its challenges, and its future.

Q: Why did P95 decide to expand to Latin America?

A: There were parallel interests that came together and created a perfect “symbiosis.” On the one hand, P95 had the idea of expanding to another geographic location to increase the geographic capacity in terms of projects and human resources. On the other hand, as Latin Americans with 20+ years of work experience in Europe, we wanted to take the skills and knowledge acquired to train people there and at the same time create work and development opportunities in the region, as well as link talented professionals with international epidemiological and clinical research companies and networks.

The idea of establishing a branch office in Latin America was a combination of both interests, and the decision to do it in Colombia was because we identified it as an important hub of talented professionals in epidemiology and public health. Clinical research centers in Colombia have shown significant development in the past 15 years and have become important for studies in Latin America and there is an open spirit to learn and further develop in epidemiology and clinical research. Also, Colombia has a large population (≈50 million people), regulations facilitate the establishment of foreign companies, and the country has had a very stable economy for more than two decades.

Q: How has the process of creating a new hub on the other side of the world been?

A: We started working with research centers and universities, which has been very interesting and enriching. It helped us confirm what we knew about Colombia: it is a country with a lot of interest in creating knowledge and professional networks. The researchers, professors, and coordinators have been very open and receptive to the idea and facilitated the process. In fact, they are very interested in a continuous collaboration.

Opening the branch in administrative and legal terms was also relatively easy. With the help of some personal contacts in Colombia and the Flanders Investment & Trade organization (FIT), we were quickly connected to several Colombian organizations, which facilitated many administrative aspects and decisions. Furthermore, Colombians are quite receptive towards development and business.

Q: What has been the most difficult and the most rewarding aspect of this process?

A: We have felt very welcome. The most rewarding thing has been identifying and creating a work team with very capable, committed professionals with a thirst for knowledge and progress. It has been especially gratifying to see how the group has integrated into P95 in such a short time, despite the distance and the challenges it poses. Also, it is encouraging to see all that has been done for research and training in epidemiology and clinical research in Colombia, resulting in leading study centers that know very well what they do (with international standards). There are many collaboration opportunities not only in the country but also in Latin America.

As there is so much potential for collaboration, perhaps a nice challenge rather than a difficulty (we see it as a luxury problem) is to identify the most efficient way to integrate local and regional project opportunities into the company's short-term global strategy.

Q: How do you see the near future for the Latin American hub? Are there plans to expand to other countries in the region?

A: The hub in Colombia is called P95 Latina because, since its creation, the intention has been to have this location as a center for Latin America. The near future includes increasing professional capacity, deploying more epidemiological studies in the region, and creating new collaborations with universities and research centers in Colombia and across the entire region.


In this interview, Thomas Verstraeten, CEO of P95, speaks about company growth, visibility and entrepreneurship, as a comment to P95’s nomination to the Trends Gazelles award 2022.

By: Alejandra Gonzalez

Ten years after being founded and two years after experiencing an unprecedented growth that even led to its expansion in Latin America, P95 received its first nomination to the Trends Gazelles. This award recognizes the fastest-growing companies in Belgium on the basis of their growth in three areas: added value, staff, and cash flow. For Tom Verstraeten, CEO of P95, this nomination “means that the growth we’ve experienced in the past year is becoming visible at the public level, which is really good.”

Indeed, visibility is one of the benefits that the Trends Gazelles nomination brings to the company. According to our CEO, “this also makes P95 more attractive for potential investors and clients that may want to do business with us. I now get emails from people saying, ‘I see you’ve been listed; do you need a board of directors? Do you need a commercial officer? I can help’. Now, more people can see that we are doing well and that we’re not just any company. P95 will feature in a long list with other successful companies.”

From the business perspective, adds Tom, getting to know some of the companies on the list of nominees brings an opportunity to learn more about what other firms outside our network are doing. “I looked up a few of the other companies on the list and some of them have developed very rapidly. Among those, you see quite a few IT companies that develop software for very specific businesses. You also find companies that create a business out of things you wouldn’t have thought of. We have limited interaction with other sectors, but this nomination gives us access to other people and allows us to learn from what they do and how they make their businesses grow.”

For those who are finding out about P95, Tom wants them to know that “this is a young and innovative company, scientifically driven, and a good place to work, because we are competitive on the job market, and this is a place where people can develop themselves and gain experience. Finally, I hope people see that we have an important role in the field of public health, that we are contributing to the improvement of public health all over the world. Yes, it’s a huge world and we are just one player, but we are doing our part, just like other players are doing theirs.”

According to Trends Gazelles, the nominated companies are not only a “source of energy to the economy” but also an “inspiration to other entrepreneurs”. For those who might need inspiration, P95’s CEO shares his advice, “if you’re willing to work hard, you’ll make it. This is what I always tell people who seek my advice on how to start work on their own. There’s work to be done everywhere, and there’s a shortage of hard-working, well-intended, qualified people. But you also need flexibility. When I started, I thought that it would be all about pharmacovigilance, but then I realized that there was a bigger need in epidemiology. Many people, like me, have an idea and think it is a critical need, but then it turns it’s not exactly what you thought it needed to be, so you need to be flexible. You have to trust yourself and know that if you do good work, there’s going to be plenty of work for you.”

COVIDRIVE welcomes three new vaccine companies to the consortium

Three new vaccine companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.

Services Portfolio People Jobs News

COVIDRIVE welcomes three new vaccine companies to the consortium

Moderna, Novavax and Valneva have joined COVIDRIVE, a public-private partnership for COVID-19 vaccine effectiveness monitoring in Europe.

 

08/02/2022 – Three new vaccine companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.

With the inclusion of these three newcomers, COVIDRIVE, which brings together public institutions, small and medium-sized enterprises and vaccine companies, has a total of 11 partners.

The new COVIDRIVE partners reflected on their participation in the consortium and the value of multi-stakeholder initiatives to monitor the effectiveness of the COVID-19 vaccines.

First, Dr Jacqueline Miller, Moderna’s Senior Vice President and Therapeutic Area Head, Infectious Disease Development, explained: “We are pleased to join the COVIDRIVE consortium and contribute to this collaboration advancing global public health. We believe that public-private partnerships play a key role in combatting the COVID-19 pandemic. As a global company, it is critical to understand data from all geographies because as we have seen throughout this pandemic, what affects one part of the world, can soon affects others. Assessing vaccine effectiveness through real-world evidence is an important tool as we try to remain ahead of the virus as it evolves.”

Moreover, Dr Seth Toback, Senior Vice President, Global Medical Affair at Novavax, commented: “Novavax is proud to join COVIDRIVE and partner across the healthcare sector in our efforts against COVID-19. We believe it is important to have multiple vaccine options available for people, particularly as we assess the need for boosters, annual revaccination, and reaching the paediatric population. This is an exciting development as we continue to work towards the development of life-saving vaccines and fight against the ongoing pandemic.”

Finally, Dr Judith Perez Gomez, Valneva’s Vice-President of Medical Affairs pointed out that “Public-private partnerships have proven to be extremely valuable for enabling R&D innovation and are even more important today as we fight the COVID-19 pandemic. We are extremely pleased to join COVIDRIVE and support Europe’s public health response through the assessment of vaccine effectiveness.”

About Moderna

Moderna is a biotechnology company based in Cambridge, Massachusetts (United States) pioneering messenger RNA (mRNA) therapeutics and vaccines. The Moderna COVID‑19 vaccine, codenamed mRNA-1273 and sold under the brand name Spikevax, received the emergency use authorisation by the U.S. Food and Drug Administration (FDA) in December 2020 and conditional marketing authorisation in the European Union by the European Medicines Agency (EMA) in January 2021. More information: www.modernatx.com.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company’s COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including Conditional Marketing Authorization from the European Commission and Emergency Use Listing from the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. More information:www.novavax.com.

About Valneva

Valneva is a specialty vaccine company based in Saint-Herblain (France) focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has developed an inactivated, adjuvanted vaccine candidate against COVID-19, VLA2001, which is currently under rolling review by the EMA. More information: www.valneva.com.

About COVIDRIVE

COVIDRIVE is a public-private partnership launched in 2021 to address the joint need to monitor COVID-19 vaccination programmes for public health institutes in Europe and to assess brand- specific COVID-19 vaccine effectiveness (CVE) for the companies as part of their regulatory obligations. For more details on COVIDRIVE please check our website www.covidrive.eu.

If you would like to request a COVID-19 vaccine effectiveness study and/or participate as a partner/study site in COVIDRIVE, send an email to the following address: info@covidrive.eu